These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 3447603

  • 1. Serum lipoprotein pattern after SAMe-treatment.
    Rini GB, Di Fede G, Rotolo G, Rizzo G, Mascellino MR, Affronti M, Delle Vedove G.
    Boll Soc Ital Biol Sper; 1987 Oct 31; 63(10):919-22. PubMed ID: 3447603
    [No Abstract] [Full Text] [Related]

  • 2. Effects of oxandrolone on plasma lipoproteins in patients with type IIa, IIb and IV hyperlipoproteinemia: occurrence of hypo-high density lipoproteinemia.
    Tamai T, Nakai T, Yamada S, Kobayashi T, Hayashi T, Kutsumi Y, Takeda R.
    Artery; 1979 Feb 31; 5(2):125-43. PubMed ID: 231951
    [Abstract] [Full Text] [Related]

  • 3. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L, Németh Csóka M, Szám I, Pados G, Karádi I, Köszegi G, Kusztos R.
    Orv Hetil; 1986 Oct 05; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract] [Full Text] [Related]

  • 4. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H, Bojanovski D.
    Artery; 1980 Oct 05; 8(2):171-8. PubMed ID: 7458684
    [Abstract] [Full Text] [Related]

  • 5. [Hyperlipoproteinemia, HDL-cholesterol and arteriosclerosis indices].
    Herrmann W, Reuter W.
    Z Gesamte Inn Med; 1982 Dec 15; 37(24):830-3. PubMed ID: 6963524
    [No Abstract] [Full Text] [Related]

  • 6. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D, Scotti L, Baroni L, Beggi P, Fasoli A.
    Clin Ter; 1980 Mar 31; 92(6):649-55. PubMed ID: 7460493
    [No Abstract] [Full Text] [Related]

  • 7. Effects of nicotinic acid therapy on high-density lipoprotein metabolism in type II and type IV hyperlipoproteinaemia.
    Packard CJ, Stewart JM, Third JL, Morgan HG, Lawrie TD, Shepherd J.
    Biochim Biophys Acta; 1980 Apr 18; 618(1):53-62. PubMed ID: 6990991
    [No Abstract] [Full Text] [Related]

  • 8. [Composition of VLDL, LDL and HDL lipoprotein fractions in type IIa, IIb, III, IV, and V hyperlipemia patients in comparison with healthy individuals].
    Hutt V, Klör HU, Wechsler JG, Ditschuneit H.
    J Clin Chem Clin Biochem; 1984 Feb 18; 22(2):141-6. PubMed ID: 6716054
    [Abstract] [Full Text] [Related]

  • 9. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G, Sirtori M, Gianfranceschi G, Frosi T, Montanari G, Sirtori CR.
    Artery; 1985 Feb 18; 12(6):363-81. PubMed ID: 4051756
    [Abstract] [Full Text] [Related]

  • 10. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Feb 18; 33(5):776-9. PubMed ID: 6683558
    [Abstract] [Full Text] [Related]

  • 11. [Gemfibrozil in the treatment of hyperlipoproteinemias].
    Monova D, Petrova V, Belovezhdov N.
    Vutr Boles; 1991 Feb 18; 30(2):56-8. PubMed ID: 1891900
    [Abstract] [Full Text] [Related]

  • 12. [Lipoprotein spectrum and makeup of the individual classes in coronary arteriosclerosis with a varying lipid level in the blood plasma].
    Gasilin VS, Kurdanov KhA, Perova NV, Torkhovskaia TI, Gadzhalova SI.
    Kardiologiia; 1980 May 18; 20(5):42-6. PubMed ID: 7392382
    [No Abstract] [Full Text] [Related]

  • 13. [Modification of serum lipoproteins by soy bean proteins].
    Richter WO, Weisweiler P, Schwandt P.
    MMW Munch Med Wochenschr; 1981 Nov 13; 123(46):1755-6. PubMed ID: 6796844
    [No Abstract] [Full Text] [Related]

  • 14. [Quantitative analysis of lipoproteins in hyperlipoproteinemias of type IIa, IIb and IV (author's transl)].
    Loeper J, Goy-Loeper J, Rouffy J.
    Clin Chim Acta; 1979 Oct 15; 98(1-2):19-26. PubMed ID: 227624
    [Abstract] [Full Text] [Related]

  • 15. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V, Calalabuig RJ, Caviola E, Soler J, Pueyo JM, Micaló T, Cano RP.
    Clin Ther; 1981 Oct 15; 4(3):192-200. PubMed ID: 7030489
    [Abstract] [Full Text] [Related]

  • 16. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Artery; 1980 Oct 15; 8(2):113-9. PubMed ID: 7458676
    [Abstract] [Full Text] [Related]

  • 17. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia].
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Oct 15; 33(12):1682-4. PubMed ID: 6686774
    [Abstract] [Full Text] [Related]

  • 18. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M.
    Przegl Lek; 1984 Oct 15; 41(7):493-9. PubMed ID: 6390536
    [No Abstract] [Full Text] [Related]

  • 19. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J, Vinzia C, Gómez JM, Morató J.
    Med Clin (Barc); 1984 May 19; 82(19):840-2. PubMed ID: 6738212
    [No Abstract] [Full Text] [Related]

  • 20. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G, Fragiacomo C, Weidmann P, Bachmann C.
    Schweiz Med Wochenschr; 1980 Dec 06; 110(49):1875-7. PubMed ID: 7455660
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.